Deneysel olarak oluşturulmuş meme tümöründe epigallokateşin-3-gallat’ın olası tedavi edici rolü
Yükleniyor...
Dosyalar
Tarih
2016
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi Sağlık Bilimleri Enstitüsü
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Meme kanserine yol açan nedenler tam olarak bilinmemekle birlikte dünyada kadınlar arasında yaygın olarak görülür. Kadınlarda görülen kanserlerin yaklaşık %29’unu oluşturmakta ve kansere bağlı ölümlerin de %14’üne neden olmaktadır. Arginaz enzimi ile argininden ornitin ve ardından poliaminler oluşur. Poliaminler kanser gelişimi yönünden tehlikeli moleküllerdir. Nitrik oksit sentaz enzimi ise arginaz ile aynı substratı kullanır ve yolağı nitrik oksit oluşumu yönüne çevirir. Nitrik oksit kansere karşı koruyucu bir molekül olarak bildirilmiştir. Antikarsinojenik özellikleri gösterilmiş olan epigallokateşin-3-gallat meme kanserine karşı koruyucu/tedavi edici bir ajan olabilir. Bu çalışmada, deneysel olarak oluşturulmuş meme tümörü dokularında; arginaz enzim aktivitesi, ornitin ve nitrik oksit düzeyleri ve endotelyal nitrik oksit skorları ile serum örneklerinde arginaz, nitrik oksit düzeyleri araştırılmıştır. Meme kanserli hayvanların serumunda artmış bulunan arginaz enzim aktivitesinin epigallokateşin-3-gallat tedavisi ile birlikte azaldığı görüldüyse de bu azalmanın istatistiksel olarak anlamlı olmadığı bulundu. Azalan nitrik oksit düzeylerinin epigallokateşin-3-gallat tedavisi ile verilen doza bağlı olarak yükseldiği saptandı. Doku arginaz enzim aktivitesi epigallokateşin-3-gallat tedavisi ile verilen doza bağlı olarak azalmıştır. Ornitin düzeyleri, tedavi gruplarında tümör gruplarına göre anlamlı olarak düşük bulundu. Epigallokateşin-3-gallat tedavisinin, doku nitrik oksit değerleri ve nitrik oksit sentaz düzeylerini arttırmasına rağmen bu artışın anlamlı olmadığı saptandı. Kanserli dokularda artan arginaz enzim aktivitesi ve ornitin miktarlarının epigallokateşin-3-gallat tedavisi ile düşmesi yine kanserde azalan nitrik oksit sentaz aktivitesinin tedavi ile artarak nitrik oksit üretiminin yükselmesine yol açması, epigallokateşin-3-gallatın meme kanseri gelişiminde koruyucu ve/veya tedavi edici bir ajan olarak kullanılabileceği düşünülmektedir. Epigallokateşin-3-gallatın bulunan bu olumlu etkilerinin ileri çalışmalar ile desteklenmesi yararlı olacaktır.
abstract
Although causes of breast cancer are not fully understood, it is commonest disease amongstthe women in the world. It constitutes approximately 29% of cancers and causes 14% of cancer-related deathsin women.The arginase enzyme forms ornithine and then polyamines from the arginine. Polyamines are dangerous molecules in terms of cancer development. Nitric oxide synthase enzyme uses the same substrate as arginase and translocates nitric oxide formation. Nitric oxide has been reported as a protective molecule against cancer development. Epigallocatechin-3-gallate,anticarcinogenic properties have been demonstrated, may be a protective/therapeutic agent against breast cancer. In this study, in the experimentally induced breast tumour tissues,arginase enzyme activity, ornithine and nitric oxide levels and endothelial nitric oxide scores; in serum samples, arginase and nitric oxide levels were investigated. Although the increased arginase enzyme activity in the serum of animals with cancer was reduced with epigallocatechin-3-gallate treatment, this reduction was not statistically significant. Decreased nitric oxide levels were found to be elevated by epigallocatechin-3-gallate treatment in the dose basis. Tissue arginase enzyme activity was decreased by epigallocatechin-3-gallate treatment in the dose basis. Ornithine levels were significantly lower in the treatment groups while it compared with tumour. Although epigallocatechin-3-gallate treatment increased tissue nitric oxide and nitric oxide synthase levels, this increase was not significant. Together with the all findings ofincreased arginase enzyme activity and ornithine levels in tumour tissues were reduced with epigallocatechin-3-gallate treatment and low nitric oxide synthase activitywas increased whichleads to an increase in the nitric oxide productionwith the same treatment may indicate to potential use of epigallocatechin-3-gallate as a protective and/or therapeutic agent in the development of breast cancer. It would be useful to investigate these positive effects of epigallocatechin-3-gallate by further studies.
abstract
Although causes of breast cancer are not fully understood, it is commonest disease amongstthe women in the world. It constitutes approximately 29% of cancers and causes 14% of cancer-related deathsin women.The arginase enzyme forms ornithine and then polyamines from the arginine. Polyamines are dangerous molecules in terms of cancer development. Nitric oxide synthase enzyme uses the same substrate as arginase and translocates nitric oxide formation. Nitric oxide has been reported as a protective molecule against cancer development. Epigallocatechin-3-gallate,anticarcinogenic properties have been demonstrated, may be a protective/therapeutic agent against breast cancer. In this study, in the experimentally induced breast tumour tissues,arginase enzyme activity, ornithine and nitric oxide levels and endothelial nitric oxide scores; in serum samples, arginase and nitric oxide levels were investigated. Although the increased arginase enzyme activity in the serum of animals with cancer was reduced with epigallocatechin-3-gallate treatment, this reduction was not statistically significant. Decreased nitric oxide levels were found to be elevated by epigallocatechin-3-gallate treatment in the dose basis. Tissue arginase enzyme activity was decreased by epigallocatechin-3-gallate treatment in the dose basis. Ornithine levels were significantly lower in the treatment groups while it compared with tumour. Although epigallocatechin-3-gallate treatment increased tissue nitric oxide and nitric oxide synthase levels, this increase was not significant. Together with the all findings ofincreased arginase enzyme activity and ornithine levels in tumour tissues were reduced with epigallocatechin-3-gallate treatment and low nitric oxide synthase activitywas increased whichleads to an increase in the nitric oxide productionwith the same treatment may indicate to potential use of epigallocatechin-3-gallate as a protective and/or therapeutic agent in the development of breast cancer. It would be useful to investigate these positive effects of epigallocatechin-3-gallate by further studies.
Açıklama
Anahtar Kelimeler
Arginaz, Epigallokateşin-3- Gallate, Meme Kanseri, Nitrik Oksit, Ornitin, Arginase, Epigallocatechin-3- Gallate, Breast Cancer, Nitric Oxide, Ornithine
